Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Core Insights - Medicenna Therapeutics Corp. will present updated clinical results from the ongoing Phase 1/2 ABILITY-1 study of MDNA11, a long-acting IL-2 super-agonist, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] - The company will also showcase preclinical data on MDNA113, a novel bifunctional anti-PD1-IL-2 Superkine, and its IL-2 agonists in glioblastoma [1][2] Presentation Details - The poster presentations will include: - Results from the ABILITY-1 monotherapy dose escalation and ongoing monotherapy expansion with MDNA11 [3] - MDNA113's mechanism as a conditionally activatable anti-PD1-IL-2 Superkine [3] - Stimulation of IL-2 signaling in glioblastomas using selective IL-2R agonists [3] About MDNA11 - MDNA11 is designed to preferentially activate immune effector cells while minimizing stimulation of immunosuppressive Tregs, achieved through specific mutations and fusion to a recombinant human albumin scaffold [4] - It is currently being evaluated in the Phase 1/2 ABILITY-1 study as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®) [4] About the ABILITY-1 Study - The ABILITY-1 study is a global, multi-center, open-label study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of MDNA11 [5][6] - The study includes a combination dose escalation with approximately 6-12 patients expected to be enrolled [5] About MDNA113 - MDNA113 is a first-in-class tumor-targeted bifunctional anti-PD1-IL-2 Superkine with high affinity for IL-13Rα2, which is overexpressed in various solid tumors [7] - The expression of IL-13Rα2 is associated with poor clinical outcomes in multiple tumor types, highlighting the potential significance of MDNA113 in cancer therapy [7] About Medicenna Therapeutics - Medicenna is focused on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, including the long-acting IL-2 Superkine MDNA11 [8] - The company has also developed bizaxofusp, which has been studied in clinical trials for recurrent glioblastoma and has received FastTrack and Orphan Drug status from the FDA [8]